methylphenidate (Concerta)

How long the methylphenidate trials actually ran

What methylphenidate is FDA approved for, and the trials behind it

Trials

6 controlled trials

Duration

1 to 7 weeks

Participants

416 children, 177 adolescents, 627 adults

Compared against

Placebo and immediate-release methylphenidate

Three double-blind, active- and placebo-controlled trials were conducted in 416 pediatric patients 6 to 12 years of age with ADHD: (1) two single-center, crossover trials (patients received each treatment for one week) (Studies 1 and 2) and (2) a multicenter, 4-week, parallel-group comparison trial (Study 3).

Verbatim from the methylphenidate FDA label, Clinical Studies section, effective August 27, 2026 — read the full label on DailyMed.

Side effects of methylphenidate in the approval trials

• Upper abdominal pain (6% vs 4% on placebo, children)
• Insomnia (3% vs 1%, children)
• Nasopharyngitis (3% vs 2%, children)
• Vomiting (3% vs 2%, children)
• Pyrexia (2% vs 1%, children)
• Decreased appetite (≥5%, adults)
• Headache (≥5%, adults)
• Dry mouth (≥5%, adults)
• Nausea (≥5%, adults)
• Anxiety (≥5%, adults)
• Dizziness (≥5%, adults)

The most common adverse reactions (≥5%) in double-blind clinical trials were: Pediatric patients: upper abdominal pain [see Table 4]. Adults: decreased appetite, headache, dry mouth, nausea, insomnia, anxiety, dizziness, weight decreased, irritability, tachycardia, and hyperhidrosis [see Table 5].

From the methylphenidate FDA label, Adverse Reactions section, effective August 27, 2026 — DailyMed.

More from the methylphenidate label: drug abuse and dependence

• Schedule II controlled substance

  Methylphenidate is a Schedule II controlled substance. The label states it has a high potential for abuse and misuse, which can lead to the development of a substance use disorder, including addiction, and that misuse of CNS stimulants can result in overdose and death — a risk increased with higher doses or unapproved routes such as snorting or injection.

  FDA label, Drug Abuse and Dependence section.

• Physical dependence and tolerance

  The label states the drug may produce physical dependence and tolerance. Withdrawal signs after abrupt discontinuation or dose reduction following prolonged use include dysphoric mood, depression, fatigue, vivid unpleasant dreams, insomnia or hypersomnia, increased appetite, and psychomotor retardation or agitation.

  FDA label, Drug Abuse and Dependence section.

• Abuse-potential studies against immediate-release methylphenidate

  In two human abuse potential studies in people with a history of recreational stimulant use, single oral doses of the extended-release tablet produced drug-liking responses statistically similar to immediate-release methylphenidate and greater than placebo; on euphoria measures the extended-release form scored lower than immediate-release in the first study. The label calls the clinical significance of these differences unknown.

  FDA label, Drug Abuse and Dependence section.

How many Americans take methylphenidate

18,572,946

prescriptions in the United States (2024), refills included

2,985,530

people filling them (2024), ± 595,666 (95%)

Correction (29 September 2026). An earlier version of this section took its numbers from ClinCalc DrugStats, a third-party site that republishes this survey; we now compute them from AHRQ’s public-use files ourselves. It said prescriptions were up 20% since 2014; that change is within the survey’s margin of error, so we no longer state a direction.

Source: AHRQ Medical Expenditure Panel Survey (MEPS), Prescribed Medicines public-use files, 2014 (HC-168A) through 2024 (HC-254A), computed by veisund. People with at least one purchase where the Multum generic name (RXDRGNAM) equals the drug, weighted by the year’s person weight; purchases include refills. Standard errors by Taylor linearization on VARSTR/VARPSU. AHRQ’s reliability rule: a year is not shown when fewer than 60 survey respondents reported the drug or the relative standard error is over 50%. AHRQ cautions that its 2018 questionnaire redesign and the 2020–2022 pandemic years make year-to-year comparisons less certain.

What people report to the FDA about methylphenidate

73,541

reports mentioning methylphenidate, all time

37,307

filed as serious (a report-level flag covering every drug and outcome in the report)

filed as serious. That flag covers the whole report, and one report can name more than one drug and more than one outcome.

Source: FDA Adverse Event Reporting System (FAERS), via openFDA, openFDA dataset refreshed 2026-07-30 (the refresh date of the query endpoint, not the date reports run through).

Drug interactions listed on the methylphenidate label

FDA label for methylphenidate, effective August 27, 2026 — DailyMed.

Who pays for methylphenidate

Two claims datasets and one survey, covering different populations with different instruments — they cannot be reconciled by arithmetic, and where their sum crowds the all-payer estimate, that is a finding about the estimates rather than a percentage.

Medicare Part D

Read the under-65 group correctly before the numbers: Medicare before 65 means the disabled and dual-eligible population — among the sickest, highest-need people in the program — and reading their utilization as typical adult use would be a category error. The beneficiary total sums brand-level rows, so treat it as an upper bound on distinct people. 158,164 beneficiaries filled 917,694 claims in 2024 — 97,573 aged 65 and over, and 60,591 under 65.

Medicaid

At least 4,818,740 prescriptions in 2024 — a floor, because 174 of 1,339 national data rows are suppressed for privacy and contribute zero. Medicaid covers more children than any insurer in the country and publishes no age split — how much of this number is pediatric use is not knowable from public data.

All payers (survey estimate)

A survey estimate from 153 respondents, which we computed from AHRQ’s MEPS 2024 Prescribed Medicines file (people with at least one purchase, weighted; purchases include refills), puts the whole country at 18,572,946 purchases and 2,985,530 people in 2024. Subtracting the public programs from it would produce a number for everyone else — and we do not print that number, because subtracting a survey from claims counts manufactures precision that does not exist.

The population nobody counts

The commercially insured working-age adult — statistically, the likeliest person to be reading this page — is the one population with no public per-drug count anywhere. Private claims data exists and is sold, but nothing a patient can check is published. For children the record is thinner still: no public source counts pediatric use of methylphenidate specifically; the closest the public record comes is condition-level treatment rates for children, which we have traced for one condition in how childhood ADHD got counted.

Sources: Medicare Part D Prescribers — by Geography and Drug, data.cms.gov, National rows, data year 2024 (published with ~17-month lag). Medicaid State Drug Utilization Data 2024, data.medicaid.gov, national aggregate rows. Retrieved 2026-09-01.

Who has been paying for methylphenidate, 2019–2024

Sources: Medicare Part D Prescribers by Geography and Drug (data.cms.gov, national rows, per data year); Medicaid State Drug Utilization Data (data.medicaid.gov, national rows). Claims, fills and beneficiaries are different units — compare each series only with itself.

The methylphenidate approval, step by step

1. Step 1

   What the approval was actually based on

   Which studies did the FDA rely on, how long did they run, and who was in them?

   CONCERTA was demonstrated to be effective in the treatment of ADHD in patients who met the Diagnostic and Statistical Manual 4th edition (DSM-IV) criteria for ADHD in the following trials: Three trials in pediatric patients 6 to 12 years old (Studies 1, 2, and 3), One trial in adolescents (13 to 18 years old), Two trials in adults (18 to 65 years old).

   FDA-approved labelling, 14 CLINICAL STUDIES 14.1 Overview of Clinical Trials — read the label on DailyMed

   Our reading

   Six trials across three age groups, which is unusually complete for this list — most drugs here were approved in adults and extrapolated to everyone else. The durations are the catch: two of the three paediatric trials were one week per treatment arm, the third was four weeks, the adolescent trial had a two-week randomised phase, and the adult trials ran five and seven weeks. This entry is anchored on Concerta, the extended-release tablet, not on the 1955 Ritalin application — different applications, different labels, and it is easy to quote one under the other.

2. Step 2

   The approval

   When was it approved, under what application, and by whose review?

   Approved

   August 1, 2000

   Application

   NDA021121

   Review

   STANDARD

   Original sponsor

   ALZA (now Janssen)

   Holds it now

   Janssen Pharmaceuticals

   Label submissions since

   31

   Source: openFDA Drugs@FDA, original application ORIG-1

3. Step 3

   What was added after it was on the market

   Which warnings arrived only after millions of people were already taking it?

   • The stimulant boxed warning was rewritten in 2023

     23 years after approval

     In May 2023 the FDA required the boxed warning on the entire prescription stimulant class — amphetamines and methylphenidates both — to be updated. The specific gap it was closing is unusual and worth knowing: the old labels did not adequately say that most people who misuse these medications get them from a family member or a peer, and that sharing them can cause a substance use disorder in the person you share them with.

     This was an update to a warning that already existed, not a new alarm about the medication working. Stimulants remain first-line treatment for ADHD.

     Worth asking

     How should I be storing this, how do we dispose of what I do not use, and how will we monitor whether my dose is still right over time.

     FDA updating warnings to improve safe use of prescription stimulants used to treat ADHD and other conditions — U.S. Food and Drug Administration (2023)

4. Step 4

   What independent research has found since

   What has been learned by people who were not selling it?

   • Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children,…

     18 years after approval

     Across 133 randomized trials, methylphenidate reduced ADHD symptoms in children and adolescents more than placebo (clinician-rated SMD -0.78, teacher-rated SMD -0.82) and was better tolerated than amphetamines, supporting it as the preferred first-choice stimulant for young people.

     Worth asking

     Why is methylphenidate usually the first-choice stimulant for children, and what specific improvements should we look for to know it is working?

     Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis — Cortese S, et al. (2018)

   • Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)

     25 years after approval

     Pooling 212 randomized trials with 16,302 children and adolescents, methylphenidate improved teacher-rated ADHD symptoms (SMD -0.74) and increased non-serious adverse events like sleep and appetite problems by about 23% without a detectable rise in serious harms, but the review rated the certainty of all of this evidence as very low.

     Worth asking

     Since trial evidence on methylphenidate is short-term and low-certainty, what improvements should we expect to see, and when would we reassess or stop if they don't appear?

     Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD) — Storebø OJ, et al. (2025)

   • Psychosis with Methylphenidate or Amphetamine in Patients with ADHD

     19 years after approval

     In 221,846 insured adolescents and young adults starting a stimulant for ADHD, new-onset psychosis occurred in about 1 in 660 patients overall, and the risk with methylphenidate (0.10%) was roughly half that with amphetamines (0.21%).

     Worth asking

     What early warning signs of psychosis should we watch for after starting methylphenidate, especially if there is any personal or family history of psychosis?

     Psychosis with Methylphenidate or Amphetamine in Patients with ADHD — Moran LV, et al. (2019)

   • Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases

     24 years after approval

     In a Swedish national study of 278,027 people with ADHD, each added year of ADHD medication use was associated with a 4% higher relative risk of cardiovascular disease, reaching about 23-27% higher risk after 3 or more years, driven mostly by hypertension and arterial disease.

     Worth asking

     If I stay on methylphenidate for several years, how often should we check my blood pressure and heart rate, and what readings would change the plan?

     Attention-Deficit/Hyperactivity Disorder Medications and Long-Term Risk of Cardiovascular Diseases — Zhang L, et al. (2024)

   • Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder:…

     17 years after approval

     In the MTA study's follow-up to about age 25 (515 people with childhood ADHD vs 258 classmates without), participants who used stimulants consistently through adolescence were on average about 2.4 cm shorter as adults than inconsistent users, without a corresponding advantage in adult ADHD symptom outcomes.

     Worth asking

     How will we track my child's height and growth curve on methylphenidate, and at what point would a dose change or medication break be worth discussing?

     Young adult outcomes in the follow-up of the multimodal treatment study of attention-deficit/hyperactivity disorder: symptom persistence, source discrepancy, and height suppression — Swanson JM, et al. (2017)

5. Step 5

   What still is not known

   Which questions you might reasonably have has nobody answered yet?

   • The longest pivotal trial was seven weeks. Stimulants are commonly taken daily for decades.
   • Two of the paediatric trials gave each treatment for one week. What does a one-week crossover tell you about year ten?
   • Effects on growth, on cardiovascular risk and on dependence accumulate over horizons no registration trial covered.